Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer HealthcarePBH -2.24%69 PS Ratio is 2.20 as of Aug. 20, 2026, which is 17% below its 10-year median of 2.65. GuruFocus rates PBH with a GF Score™ of 69/100 and a GF Value™ of $70.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 949 Drug Manufacturers companies, Prestige Consumer Healthcare ranks better than 51.63% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Prestige Consumer Healthcare's share price is $50.52.
Prestige Consumer Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $22.94. Hence, Prestige Consumer Healthcare's PS Ratio for today is 2.20.
Good Sign:
Prestige Consumer Healthcare Inc stock PS Ratio (=2.25) is close to 5-year low of 2.09.
The historical rank and industry rank for Prestige Consumer Healthcare's PS Ratio or its related term are showing as below:
PBH'
s PS Ratio Range Over the Past 10 Years
Min: 1.44 Med: 2.65 Max: 3.99
Current: 2.21
During the past 13 years, Prestige Consumer Healthcare's highest PS Ratio was 3.99. The lowest was 1.44. And the median was 2.65.
PBH's PS Ratio is ranked better than 51.63% of 949
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs PBH: 2.21
During the past 13 years, Prestige Consumer Healthcare's highest 3-Year average Revenue per Share Growth Rate was 116.50% per year. The lowest was -14.60% per year. And the median was 7.30% per year.
Prestige Consumer Healthcare (NYSE:PBH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Prestige Consumer Healthcare PS Ratio Related Terms
Prestige Consumer Healthcare PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's PS Ratio distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Prestige Consumer Healthcare's Share Price of today is $50.52. Prestige Consumer Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Prestige Consumer Healthcare (PBH) has a PS Ratio of 2.20 as of Aug. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Prestige Consumer Healthcare and its competitors. This is 17% below median its historical median of 2.65. Over the past decade, Prestige Consumer Healthcare's PS Ratio has ranged from 1.44 to 3.99. According to the industry distribution chart, Prestige Consumer Healthcare ranks #459 out of 949 companies in the Drug Manufacturers industry, placing it in the top 48.4%.
Is Prestige Consumer Healthcare's PS Ratio too high?
Prestige Consumer Healthcare's current PS Ratio of 2.20 is 17% below median its 10-year median of 2.65. Over the past 10 years, this metric has ranged from a low of 1.44 to a high of 3.99. The Drug Manufacturers industry median PS Ratio is 2.35. Prestige Consumer Healthcare's value of 2.20 is 6.4% below this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #459 out of 949 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's PS Ratio compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #459 out of 949 companies for PS Ratio. This puts Prestige Consumer Healthcare in the upper half of its industry. The industry median PS Ratio is 2.35. Prestige Consumer Healthcare's value of 2.20 is 6.4% below this benchmark. Historically, Prestige Consumer Healthcare's own PS Ratio has ranged from 1.44 to 3.99 over the past decade. While the company's 10-year median is 2.65 vs. the industry median of 2.35, Prestige Consumer Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current PS Ratio of 2.20 is 6.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current PS Ratio is 2.20, which is 17% below median its own 10-year median of 2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current PS Ratio is 2.20, which is 17% below median its 10-year median of 2.65 and 6.4% below the Drug Manufacturers industry median of 2.35. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current PS Ratio is 2.20 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
PS Ratio: 2.20 (17% below median its 10-year median of 2.65)
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
Industry Position: 6.4% below the Drug Manufacturers median (#459 of 949)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
